James Carmichael
Impact in
- Oncology top 0.1%
- PARP inhibition in cancer therapy
- Lung Cancer Research Studies
- Drug Transport and Resistance Mechanisms
- Cancer Research top 1%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 24
- PARP inhibition in cancer therapy 10
- Drug Transport and Resistance Mechanisms 4
- Cancer Treatment and Pharmacology 3
- Colorectal Cancer Treatments and Studies 3
-
- Pharmacogenetics and Drug Metabolism 4
- Co-authors
- William DeGraff (6 shared papers)John Dorrance Minna (3 shared papers)Adi F. Gazdar (3 shared papers)Andrew N.J. Tutt (4 shared papers)Michael Leonard Friedlander (4 shared papers)Stan B. Kaye (4 shared papers)Ursula A. Matulonis (3 shared papers)Timothy Anthony Yap (3 shared papers)
- Journals
- Journal of Clinical Oncology (9 papers)International Journal of Radiation Oncology*Biology*Physics (8 papers)Cancer Chemotherapy and Pharmacology (6 papers)The Lancet (2 papers)The Lancet Oncology (2 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
James Carmichael
68 papers receiving 17.4k citations
James Carmichael's Hit Papers
Peers
Comparison fields: 5 of 106
- Oncology 6.0k
- Cancer Research 1.2k
- Reproductive Medicine 1.0k
- Genetics 1.4k
- Molecular Biology 1.6k
Countries citing papers authored by James Carmichael
This map shows the geographic impact of James Carmichael's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Carmichael with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Carmichael more than expected).
Fields of papers citing papers by James Carmichael
This network shows the impact of papers produced by James Carmichael. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Carmichael. The network helps show where James Carmichael may publish in the future.
Co-authors
The 25 scholars most cited alongside James Carmichael, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 69 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Hit paper breakdown → | 1987 | 3563 |
| 2 | Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers Hit paper breakdown → | 2009 | 3069 |
| 3 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Hit paper breakdown → | 2010 | 1955 |
| 4 | Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer Hit paper breakdown → | 2012 | 1554 |
| 5 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Hit paper breakdown → | 2010 | 1453 |
| 6 | Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Hit paper breakdown → | 2011 | 966 |
| 7 | Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval Hit paper breakdown → | 2010 | 854 |
| 8 | 1999 | 787 | |
| 9 | Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Hit paper breakdown → | 1987 | 635 |
| 10 | 2011 | 408 | |
| 11 | 2008 | 294 | |
| 12 | 2002 | 226 | |
| 13 | Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. | 2002 | 186 |
| 14 | 2008 | 182 | |
| 15 | 2013 | 170 | |
| 16 | 2011 | 142 | |
| 17 | 1989 | 130 | |
| 18 | 2004 | 123 | |
| 19 | 1992 | 97 | |
| 20 | 2013 | 80 |
About James Carmichael
James Carmichael is a scholar working on Oncology, Pharmacology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Cancer Research, having authored 69 papers that have together received 18.2k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (10 papers), Nausea and vomiting management (5 papers), Drug Transport and Resistance Mechanisms (4 papers), Pharmacogenetics and Drug Metabolism (4 papers), Cancer Treatment and Pharmacology (3 papers), Colorectal Cancer Treatments and Studies (3 papers), Glutathione Transferases and Polymorphisms (2 papers) and Asthma and respiratory diseases (2 papers). The work is most often cited by research in Oncology (6.0k citations), Cancer Research (1.2k citations), Reproductive Medicine (1.0k citations), Genetics (1.4k citations) and Molecular Biology (1.6k citations). James Carmichael has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include William DeGraff, John Dorrance Minna, Adi F. Gazdar, Andrew N.J. Tutt, Michael Leonard Friedlander, Stan B. Kaye, Ursula A. Matulonis, Timothy Anthony Yap, Jan H.M. Schellens and Mark Wickens. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics, Cancer Chemotherapy and Pharmacology, The Lancet and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.